Radioactive seeds aim to boost tumor control in patients with 6-10 metastases
NCT ID NCT07333664
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding image-guided radioactive seed implants to standard cancer therapy can improve disease control in patients with 6 to 10 metastatic tumors. About 120 adults with solid tumors that have spread will be randomly assigned to receive either standard therapy alone or standard therapy plus the seed implants. The study will measure progression-free survival, overall survival, safety, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iodine-125 radioactive seeds
What this could lead to
If it works, this could offer a new way to control multiple metastatic tumors by combining standard drugs with targeted radiation implants.
What could go wrong
This is an early phase 2 study with only 120 participants, so results may not apply to everyone. The procedure carries risks like radiation exposure or damage to nearby organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The 960th Hospital of People's Liberation Army (PLA)
Jinan, Shandong, 250031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••